Complete Guide to Concizumab Pharmacokinetics
Overview
Concizumab is a mAb used in the Hematology therapeutic area. It is indicated for Hemophilia. PK/PD simulator for concizumab (Alhemo) in hemophilia. TMDD model with TFPI suppression visualization.
Mechanism of Action
Concizumab exerts its pharmacological effect by targeting TFPI. As a mAb, it modulates this target to achieve therapeutic efficacy in Hemophilia. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
The following parameters are derived from published PK/PD models for Concizumab:
| Parameter | Value |
|---|---|
| IC50 | 2 nM |
| Imax | 0.95 fraction |
| kdegs | 1.18 1/day |
| sTFPI baseline | 1.6 nM |
| F | 0.93 fraction |
| Q | 0.3 L/day |
| Ka | 0.25 1/day |
| Km | 5 nM |
| Vc | 3 L |
| Vp | 2.5 L |
| Vmax | 1.5 nmol/day/L |
| CL linear | 0.15 L/day |
Parameters represent typical population estimates from published literature. Individual values may vary.
Dosing & Administration
Concizumab is administered via the SC route. Subcutaneous administration provides sustained absorption from the injection site. Bioavailability and absorption rate may vary by injection site and volume.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Hematology therapeutic area, for the treatment of Hemophilia, understanding the pharmacokinetics of Concizumab is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Concizumab pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
Interactive Concizumab PK Simulator
Explore Concizumab pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Concizumab?
The elimination half-life of Concizumab depends on patient-specific factors. Use our interactive Concizumab PK simulator to explore concentration-time profiles and estimate half-life under different dosing scenarios.
How is Concizumab administered?
Concizumab is administered via the SC route. It is indicated for Hemophilia. As a mAb, dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Concizumab?
Key pharmacokinetic parameters for Concizumab include clearance (CL), volume of distribution (Vd), and elimination half-life. See the PK Parameters section above for specific values from published models.
Can I simulate Concizumab dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Concizumab PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.